Boundless Bio Presents Preclinical And Clinical Pharmacodynamic Data On Lead EcDNA-Directed Therapy, BBI-355, At AACR Annual Meeting 2024
Boundless Bio Presents Preclinical And Clinical Pharmacodynamic Data On Lead EcDNA-Directed Therapy, BBI-355, At AACR Annual Meeting 2024
Boundless Bio在2024年AACR年會上公佈了主要的eCDNA導向療法 BBI-355 的臨床前和臨床藥效學數據
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled oncogene amplified cancers
研究結果支持正在開發的新型、口服、選擇性檢查點激酶 1 (CHK1) 抑制劑 BBI-355，目前處於第 1/2 期開發階段，可作爲基於 eCDNA 的癌基因擴增癌症的差異化治療方法
Third poster presentation to highlight the potential role of ecDNA-based resistance to chemotherapy
第三張海報展示將重點介紹基於 eCDNA 的化療耐藥性的潛在作用
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。